Search research articles

ACERCA DE JoVE

Visión General Liderazgo Blog Centro de Ayuda JoVE

AUTORES

Proceso de Publicación Consejo Editorial Alcance y Políticas Revisión por Pares Preguntas Frecuentes Enviar

BIBLIOTECARIOS

Testimonios Suscripciones Acceso Recursos Consejo Asesor de Bibliotecas Preguntas Frecuentes

INVESTIGACIÓN

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archivo

EDUCACIÓN

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Centro de Recursos para Profesores Sitio de Profesores

Términos y Condiciones de Uso

Política de Privacidad

Videos de Conceptos Relacionados

Heart Failure V: Medical Management

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...

Cardiopulmonary Resuscitation IV: Pharmacological Management

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...

Blood Pressure Imbalances and Circulatory Shock

Blood Pressure Imbalances and Circulatory Shock

Disorders affecting blood volume, vascular tone, or vascular function can disrupt vascular homeostasis, including conditions like hypertension, hemorrhage, and shock.
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...

Heart Failure VI: Adjunct Therapies

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.

Cardiomyopathy II: Dilated Cardiomyopathy

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...

Cardiomyopathy V: Interprofessional Care

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por

Same author

Taking Bold Steps for Meaningful Changes in Transplant Cardiology Fellowship Training.

Clinical transplantation·2026

Same author

THE SOCIETY OF CRITICAL CARE CARDIOLOGY - RATIONALE, BLUEPRINT, AND LESSONS LEARNED IN THE CREATION OF A NEW MULTIDISCIPLINARY PROFESSIONAL ORGANIZATION.

American heart journal·2026

Same author

Clinical Characteristics and Outcomes of Older Patients Admitted to the Cardiac Intensive Care Unit.

JACC. Advances·2026

Same author

Associations Between Admission C-Reactive Protein and In-Hospital Mortality Amongst Patients with Cardiogenic Shock.

European heart journal. Acute cardiovascular care·2026

Same author

Early Corticosteroid use and Clinical Outcomes in Patients with Mixed and Cardiogenic Shock.

Journal of intensive care medicine·2026

Same author

Impact of malnutrition on outcomes among elderly ST-Elevation myocardial infarction patients receiving primary percutaneous coronary intervention.

American heart journal·2026

Search research articles

Video Experimental Relacionado

Updated: Sep 4, 2025

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

El aumento y disminución del apoyo circulatorio mecánico temporal en el choque cardiogénico: una declaración

Bram J Geller, Shashank S Sinha, Navin K Kapur

|July 21, 2022

Resumen

El apoyo circulatorio mecánico temporal se utiliza cada vez más para el choque cardiogénico, pero la evidencia es limitada. Esta declaración ofrece orientación práctica sobre la selección del dispositivo, la escalada y el destete para pacientes con insuficiencia cardíaca y ataque cardíaco.

Palabras clave:

Declaraciones científicas de la AHA toma de decisiones clínicas oxigenación de la membrana extracorpórea insuficiencia cardíaca Dispositivos de ayuda cardíaca Bombaje con globo intra-aórtico choque, cardiogénico

Más Videos Relacionados

The Intra-Aortic Balloon Pump

The Intra-Aortic Balloon Pump

Published on: February 5, 2021

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

Videos de Experimentos Relacionados

Last Updated: Sep 4, 2025

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

The Intra-Aortic Balloon Pump

The Intra-Aortic Balloon Pump

Published on: February 5, 2021

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

Área de la Ciencia:

Cardiología
Medicina de cuidados intensivos
Apoyo circulatorio mecánico

Sus antecedentes:

El uso de apoyo circulatorio mecánico temporal (MCS) en el choque cardiogénico está aumentando rápidamente.
La toma de decisiones clínicas carece de pruebas sólidas de ensayos controlados aleatorios.
Las directrices de la sociedad profesional para la escalada / desescalada de MCS son escasas.

Objetivo del estudio:

Proporcionar sugerencias pragmáticas para la selección, la escalada y el destete de dispositivos MCS temporales.
Ofrecer orientación para pacientes con insuficiencia cardíaca aguda descompensada y infarto agudo de miocardio.
Establecer enfoques estandarizados para el uso temporal de MCS a la espera de nuevos datos clínicos.

Principales métodos:

Esta declaración científica sintetiza los conocimientos actuales y las opiniones de los expertos.
Se centra en las causas comunes del shock cardiogénico.
Su objetivo es orientar la práctica clínica en ausencia de datos definitivos de ensayos.

Principales resultados:

Proporciona recomendaciones prácticas para la gestión temporal de la MCS.
Aborda la selección de dispositivos, la escalada y las estrategias de destete.
Destaca la necesidad de enfoques estandarizados.

Conclusiones:

El apoyo circulatorio mecánico temporal es una intervención crítica en el choque cardiogénico.
Se necesitan estrategias estandarizadas y basadas en la evidencia para obtener resultados óptimos para los pacientes.
Esta declaración sirve como recurso clínico hasta que estén disponibles más datos aleatorios.